Equities researchers at Jefferies Financial Group began coverage on shares of PMV Pharmaceuticals (NASDAQ:PMVP - Get Free Report) in a research note issued to investors on Friday, Marketbeat.com reports. The brokerage set a "buy" rating and a $5.00 price target on the stock. Jefferies Financial Group's price objective would indicate a potential upside of 179.33% from the company's previous close.
A number of other analysts have also recently commented on the stock. HC Wainwright reissued a "buy" rating and set a $5.00 target price on shares of PMV Pharmaceuticals in a research note on Thursday, March 7th. LADENBURG THALM/SH SH initiated coverage on shares of PMV Pharmaceuticals in a research note on Wednesday, December 27th. They set a "buy" rating and a $7.00 target price for the company.
Read Our Latest Report on PMVP
PMV Pharmaceuticals Trading Up 13.3 %
PMVP traded up $0.21 on Friday, reaching $1.79. The stock had a trading volume of 1,703,275 shares, compared to its average volume of 556,125. PMV Pharmaceuticals has a 12-month low of $1.18 and a 12-month high of $9.72. The business's 50-day moving average price is $1.69 and its two-hundred day moving average price is $2.33. The company has a market cap of $92.08 million, a P/E ratio of -1.23 and a beta of 1.65.
PMV Pharmaceuticals (NASDAQ:PMVP - Get Free Report) last released its quarterly earnings data on Thursday, February 29th. The company reported ($0.31) earnings per share for the quarter, beating analysts' consensus estimates of ($0.39) by $0.08. As a group, analysts predict that PMV Pharmaceuticals will post -1.47 earnings per share for the current year.
Institutional Trading of PMV Pharmaceuticals
Institutional investors and hedge funds have recently modified their holdings of the stock. State Street Corp grew its stake in PMV Pharmaceuticals by 101.6% during the 2nd quarter. State Street Corp now owns 5,171,490 shares of the company's stock valued at $73,694,000 after acquiring an additional 2,605,945 shares in the last quarter. Alkeon Capital Management LLC grew its stake in PMV Pharmaceuticals by 58.6% during the 3rd quarter. Alkeon Capital Management LLC now owns 2,347,414 shares of the company's stock valued at $14,413,000 after acquiring an additional 867,547 shares in the last quarter. Point72 Asset Management L.P. purchased a new stake in PMV Pharmaceuticals during the 4th quarter valued at about $2,325,000. BlackRock Inc. grew its stake in PMV Pharmaceuticals by 16.1% during the 2nd quarter. BlackRock Inc. now owns 4,677,028 shares of the company's stock valued at $29,278,000 after acquiring an additional 646,859 shares in the last quarter. Finally, Woodline Partners LP grew its stake in PMV Pharmaceuticals by 317.2% during the 2nd quarter. Woodline Partners LP now owns 733,735 shares of the company's stock valued at $4,593,000 after acquiring an additional 557,847 shares in the last quarter. Hedge funds and other institutional investors own 90.20% of the company's stock.
About PMV Pharmaceuticals
(
Get Free Report)
PMV Pharmaceuticals, Inc, a precision oncology company, engages in the discovery and development of small molecule and tumor-agnostic therapies for p53 mutations in cancer. It's lead product candidate is PC14586, a small molecule that corrects mutant p53 protein containing the Y220C mutation and restores wild-type p53 function.
Read More
Before you consider PMV Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and PMV Pharmaceuticals wasn't on the list.
While PMV Pharmaceuticals currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Thinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.
Get This Free Report
